Psychopharmacology: Progress and Promise for the MDMA Drug Development Program

Summary: Scientific journal Psychopharmacology publishes MAPS’ MDMA research results, highlighting ongoing progress for MDMA drug development. The publication written by MAPS Public Benefit Corporation (MPBC) Clinical Data Scientist Alli Feduccia, Ph.D., MAPS Public Benefit Corporation (MPBC) Medical Monitor and Clinical Investigator Michael Mithoefer, M.D., and Psychiatrist Julie Holland, M.D., details research results from Phase 2 clinical trials and upcoming plans for Phase 3 trials of MDMA-assisted psychotherapy for posttraumatic stress disorder (PTSD).

“Over a century after the discovery of 3,4-methylenedioxymethamphetamine (MDMA), a significant milestone has recently been reached in the unique history of this compound. Based on favorable results of a series of phase 2 studies, MDMA is now advancing to phase 3 clinical trials as a pharmacological agent to enhance psychotherapy.”

“Following decades of sparse research, renewed interest in the use of psychoactive agents such as MDMA and other psychedelic is growing rapidly across the globe as findings from randomized controlled trials bring evidence of safety and efficacy in treating PTSD, depression, anxiety and addictive disorders.”

View the Publication